Compare PUMP & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PUMP | GERN |
|---|---|---|
| Founded | 2007 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 808.3M |
| IPO Year | 2017 | N/A |
| Metric | PUMP | GERN |
|---|---|---|
| Price | $15.03 | $1.26 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 3 |
| Target Price | ★ $14.14 | $2.17 |
| AVG Volume (30 Days) | 6.2M | ★ 13.9M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,269,158,000.00 | N/A |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | $15.61 | $43.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.51 | $1.04 |
| 52 Week High | $18.50 | $2.01 |
| Indicator | PUMP | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 41.43 | 34.40 |
| Support Level | $14.90 | $1.22 |
| Resistance Level | $15.34 | $1.29 |
| Average True Range (ATR) | 0.92 | 0.06 |
| MACD | -0.32 | -0.00 |
| Stochastic Oscillator | 6.22 | 21.15 |
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.